T1	Participants 368 413	Chinese patients with essential hypertension.
T2	Participants 556 613	105 patients with mild or moderate essential hypertension
T3	Participants 851 970	Only those patients who have finished 8 weeks of active treatment in both groups were included into the final analysis.
T4	Participants 979 1075	One hundred one patients (51 in enalapril group and 50 in indapamide group) completed the study.
